This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Actonel

Allergan plc

Drug Names(s): Benet (Japan), NE58095

Description: Actonel 150 mg once-a-month, Actonel 35 mg Once-a-Week and Actonel 5 mg daily are indicated for the prevention and treatment of osteoporosis in postmenopausal women. Actonel 5 mg daily is also indicated for the prevention and treatment of glucocorticoid-induced osteoporosis (GIO) in men and women either initiating or continuing systemic glucocorticoid treatment (greater than or equal to 7.5 mg/d prednisone or equivalent) for chronic diseases.

Actonel is a pyridinyl bisphosphonate that inhibits osteoclast-mediated bone resorption and modulates bone metabolism. Thus, it reduces bone turnover, improves bone mineralization, and increases bone mass.

Deal Structure: Revenue splits for this drug are BioMedTracker estimates.

Norwich and Proctor & Gamble
Actonel was originally synthesized by Norwich Eaton Pharmaceuticals (then a subsidiary of The Procter & Gamble Company).

Proctor & Gamble and Gamble and Hoeschst
In May 1997, Procter & Gamble and Hoechst Marion Roussel announced that they formed a global alliance to commercialise Actonel. The companies said they will work together to complete clinical studies, obtain regulatory approvals and develop sales and marketing plans to launch Actonel for osteoporosis and other bone diseases in all countries except Japan. The agreement is effective immediately, and will last until 2015. As part of the agreement, Hoechst Marion Roussel will make milestone payments to P&G to help offset P&G's investment to date in this therapy. The two companies will share future expenses and revenues for Actonel. No other financial terms were disclosed.

Ajinomoto, Takeda, and...See full deal structure in Biomedtracker

Partners: Sanofi Takeda Pharmaceutical Company Ltd Ajinomoto Pharmaceuticals Co., Ltd. Eisai Co., Ltd.


Actonel News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug